Compound News and Research

RSS

Anthem submits new insurance rate plan in Calif. after earlier effort rebuffed

The Los Angeles Times: "Embattled health insurer Anthem Blue Cross is reviving its plan to raise rates for tens of thousands of California policyholders, some of whom could see their premiums rise as much as 20%. California's largest for-profit insurer submitted new rates Wednesday amid pressure to scale back increases of as much as 39% that had provoked fury from consumers, lawmakers and even President Obama" and helped revive the effort to pass a national health care law.

2 Jul 2010

Healthy diet can reduce age-related eye problems

While 20/20 vision is a symbol of visual acuity, between now and the year 2020, more and more people will experience some extent of vision loss due to age-related macular degeneration (AMD) and other sight-robbing diseases.

2 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

For the first time, scientists have linked a brain compound called kynurenic acid to cognition, possibly opening doors for new ways to enhance memory function and treat catastrophic brain diseases, according to a new study from the University of Maryland School of Medicine. When researchers decreased the levels of kynurenic acid in the brains of mice, their cognition was shown to improve markedly, according to the study, which was published in the July issue of the journal Neuropsychopharmacology.

1 Jul 2010

Sanofi-aventis signs agreement to acquire TargeGen

TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis. Under the agreement, the ultimate purchase price will depend on the achievement of certain future milestones events and will total $560M if such milestones are fully realized. The closing of the transaction is expected to occur in the 3rd quarter of 2010.

1 Jul 2010

Bortezomib may offer hope for treating inflammatory diseases: New research

Those looking for a new treatment for a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus may need to look no further than a drug already available for treating cancer. In a research report published in the July 2010 print issue of the Journal of Leukocyte Biology, Japanese scientists use mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

1 Jul 2010

Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

30 Jun 2010

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.

30 Jun 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

New chemical method for drug design, agrichemicals

University of Delaware scientist Donald Watson is part of a research team that has discovered an easier method for incorporating fluorine into organic molecules, giving chemists an important new tool in developing materials ranging from new medicines to agricultural chemicals.

30 Jun 2010

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.

30 Jun 2010

Aeolus AEOL 10150 study confirms ability to rescue skin from deleterious effects of CEES

Aeolus Pharmaceuticals, Inc. reported that researchers from National Jewish Health and the University of Colorado Anschutz Medical Campus have completed studies demonstrating that AEOL 10150 provides statistically significant protection of the skin in the 2-chloroethyl-ethylsulfide (CEES; half mustard) model of mustard gas exposure in mice and in a human cell culture model.

30 Jun 2010

Metabolex, Sanofi-Aventis sign global license deal to develop GPR119 for type 2 diabetes treatment

Metabolex and Sanofi-Aventis announced today that they have entered into a global license and development agreement for the research, development, manufacture and commercialization of small molecules that modulate the G-protein coupled receptor 119 (GPR119), a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion.

30 Jun 2010

Recent, upcoming FDA efforts address rare, 'neglected' diseases

The FDA's new rare disease review group will hold its first public hearing on Tuesday and Wednesday to discuss how to expand efforts to develop treatments for rare diseases that affect fewer than 200,000 people, Reuters

30 Jun 2010

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

29 Jun 2010

New tool could aid in diagnosing Alzheimer's, track disease progression

A trial of a novel radioactive compound readily and safely distinguished the brains of Alzheimer's disease patients from healthy volunteers on brain scans and opens the doors to making such imaging available beyond facilities that can manufacture their own radioactive compounds.

29 Jun 2010

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to placebo plus insulin (with or without OADs).

29 Jun 2010

Image-guided percutaneous biopsies on the rise

Advanced imaging technologies have helped shift biopsy techniques away from more invasive approaches toward imaging-guided percutaneous-or through the skin-techniques, according to a new study appearing online and in the September print edition of the journal Radiology.

29 Jun 2010

Marine organisms may hold key to fight malaria

University of Central Florida scientist Debopam Chakrabarti is analyzing more than 2,500 samples from marine organisms collected off deep sea near Florida's coast. Some of them could hold the key to developing drugs to fight malaria, a mosquito-borne illness that kills more than 1 million people worldwide annually.

29 Jun 2010

Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program

Marcadia Biotech, Inc. and Eli Lilly and Company today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe hypoglycemia. The program includes MAR531, a glucagon analog that is in preclinical development at Marcadia, as well as related backup compounds.

29 Jun 2010

Compound News and Research

Anthem submits new insurance rate plan in Calif. after earlier effort rebuffed

Healthy diet can reduce age-related eye problems

Advanced Cancer Therapeutics secures $10M in investments

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

Sanofi-aventis signs agreement to acquire TargeGen

Bortezomib may offer hope for treating inflammatory diseases: New research

Investment report on BioCryst Pharmaceuticals

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

New chemical method for drug design, agrichemicals

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Aeolus AEOL 10150 study confirms ability to rescue skin from deleterious effects of CEES

Metabolex, Sanofi-Aventis sign global license deal to develop GPR119 for type 2 diabetes treatment

Recent, upcoming FDA efforts address rare, 'neglected' diseases

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

New tool could aid in diagnosing Alzheimer's, track disease progression

Dapagliflozin in addition to insulin improves glycemic control in type 2 diabetics

Image-guided percutaneous biopsies on the rise

Marine organisms may hold key to fight malaria

Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News